NYSE
$80.08▼ 1.18%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $33.57BShares out 4.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.14Overnight26.10.14 10:134Ownership#●●●
Zoetis Inc.
Kristin C. Peck, an executive at Zoetis Inc., filed a Form 4 on October 13, 2026, reporting a change in beneficial ownership of securities as of October 9, 2026. This filing is a routine disclosure of insider transactions and does not indicate any material changes to the company's financial position or corporate governance.…more
$80.08-1.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Overnight26.10.14 10:134Ownership
Zoetis Inc.
Kevin Esch, an executive at Zoetis Inc., filed an SEC Form 4 on October 13, 2026, reporting a change in beneficial ownership of company securities as of October 9, 2026. This filing serves as a standard disclosure of insider stock holdings.…more
$80.08-1.18%vs prev closeView filingShare - 10.14Overnight26.10.14 10:134Ownership
Zoetis Inc.
Insider Rimma Driscoll of Zoetis Inc. reported a change in beneficial ownership of company securities on October 9, 2026. This filing is a standard Form 4 report detailing the change in the insider's equity holdings.…more
$80.08-1.18%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoRegular26.10.20 23:09Bullish#●●●#●●●
FDA Approves Ready-To-Use Cefovecin Injectable For Dogs
The FDA has approved a ready-to-use cefovecin injectable for the treatment of certain skin infections in dogs. This approval expands the available veterinary treatment options and strengthens the company's product portfolio.…more
$80.08-1.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6Pre-market26.10.06 20:32
●●●●●●●● ●●●●● ●●●●●●
Zoetis announced that dogs treated with Simparica Trio showed a significantly lower adult heartworm infection rate compared to those on NexGard Plus in a drug-resistant study. This data highlights the clinical efficacy of the product, potentially strengthening its competitive position in the veterinary market.…more
$80.08-1.18%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report